Methods of treating disease states using antiangiogenic agents

a technology of angiogenesis and disease state, applied in the field of angiogenesis treatment of disease state, can solve the problem that the estrogenic 2-hydroxyl derivative cannot be demethylated, and achieve the effect of improving absorption, transport, and reducing toxicity

Inactive Publication Date: 2007-01-11
ENTRE MED INC
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0042] The present invention provides certain analogs of 2-methoxyestradiol that are effective in treating diseases characterized by abnormal mitosis and / or abnormal angiogenesis. Specifically the present invention relates to analogs of 2-methoxyestradiol that have been modified at the 2, 3 and 17 positions thereof. Compounds within the general formulae that inhibit cell proliferation are preferred. Compounds within Formula I that inhibit angiogenesis are also preferred. Preferred compositions may also exhibit a change (increase or decrease) in estrogen receptor binding, improved absorption, transport (e.g., through blood-brain barrier and cellular membranes), biological stability, or decreased toxicity. The invention also provides compounds useful in the method, as described by the general formulae of the claims.

Problems solved by technology

Replacement of the 2-methoxy group by other moieties, such as a propynyl group, retains antiproliferative activity, but these groups cannot be de-methylated to yield the estrogenic 2-hydroxyl derivatives.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating disease states using antiangiogenic agents
  • Methods of treating disease states using antiangiogenic agents
  • Methods of treating disease states using antiangiogenic agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0127] The procedures described below are for specific compounds. However, these reactions can be applied to all examples in this patent by one skilled in the art. References to compound #s below correspond to the numbers assigned to the compounds shown in the synthesis Schemes 1-7 above.

[0128] Representative oxidation of estradiol analogs to estrone analogs: 2-ethoxyestra-1,3,5(10)-trien-3-ol-17-one (Compound #5): 2-Ethoxyestra-1,3,5(10)-trien-3,17-diol (#2, 1.88 g, 5.67 mmol) was placed in a 250 mL round bottom flask that was equipped with a 25 mT Dean-Stark trap and a reflux condenser. The entire apparatus had been flame dried under an argon atmosphere. Toluene (50 mL) was added to dissolve the starting material. Aluminum isopropoxide (5.7 g, 28.4 mmol) and cyclohexanone (23.5 mL, 2.26.8 mmol) were added and the entire reaction mixture was heated at reflux (145-150° C.) for 20 h. Saturated aqueous sodium bicarbonate solution (100 mL) was added after the reaction mixture was allo...

example 2

[0167] Determination of in vitro anti-proliferative activity of substituted estradiol analogs: In vitro anti-proliferative or anti-mitogenic activity was determined using a commercially available cell-based assay in 96-well tissue culture plates with assessment of proliferation by evaluating DNA synthesis through incorporation into DNA of immuno-reactive (BrdU) nucleotides. The cell types used are commercially available (MDA-MB-231: breast cancer; U87-MG: glioblastoma; PC3: prostate cancer; HUVEC: non-transformed early passage human umbilical vein endothelial cells). These assays, and the many assay variations possible to determine in vitro anti-proliferative or anti-mitogenic activity, are well known to those skilled in the art. The concentration which causes 50% inhibition of proliferation (IC50) was estimated from a does-response curve generally carried out with a range of concentrations from ≧100 microg / mL to ≦0.01 microg / mL. The results of the tests are shown below in Table IV....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
diameteraaaaaaaaaa
sizeaaaaaaaaaa
Login to view more

Abstract

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] The present application claims benefit of provisional patent application Ser. No. 60 / 474,288 filed May 28, 2003.FIELD OF THE INVENTION [0002] The present invention relates to treating disease states characterized by abnormal cell mitosis and to treating disease states characterized by abnormal angiogenesis and to treating disease states characterized by a combination of these events. More particularly, the present invention relates to analogs of 2-methoxyestradiol (2ME2) and their effect on diseases characterized by abnormal cell mitosis and / or abnormal angiogenesis. BACKGROUND OF THE INVENTION [0003] Angiogenesis is the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans and animals undergo angiogenesis only in very specific, restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development, and formation of the corpus luteum, endomet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/56C07J1/00A61KC07J3/00C07J7/00C07J31/00C07J41/00
CPCC07J41/00A61P1/00A61P1/04A61P1/16A61P11/00A61P13/02A61P13/08A61P13/12A61P15/00A61P17/00A61P17/06A61P19/02A61P21/00A61P25/00A61P27/02A61P27/06A61P29/00A61P31/00A61P31/04A61P31/10A61P31/18A61P31/22A61P35/00A61P35/02A61P37/02A61P37/06A61P37/08A61P7/02A61P7/06A61P9/00A61P9/10
Inventor AGOSTON, GREGORYLAVALLEE, THERESAPRIBLUDA, VICTORSHAH, JAMSHEDTRESTON, ANTHONY
Owner ENTRE MED INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap